Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (3)
- Doctoral Thesis (2)
Language
- English (5) (remove)
Keywords
- Legionella pneumophila (5) (remove)
The bacterial pathogen Legionella pneumophila replicates intracellularly in protozoa, but can also cause severe pneumonia, called Legionnaires' disease. The bacteria invade and proliferate in the alveolar macrophages of the human lung. L. pneumophila bacteria exhibit a biphasic life cycle: replicative bacteria are avirulent; in contrast, transmissive bacteria express virulence traits and flagella. Primarily aim of this thesis was to evaluate the impact of the regulatory proteins FleQ, FleR, and RpoN in flagellar gene regulation. Phenotypic analysis, Western blot and electron microscopy of regulatory mutants in the genes coding for FleQ, RpoN and FleR demonstrated that flagellin expression is strongly repressed and that these mutants are non-flagellated in transmissive phase. Transcriptomic studies of these putative flagellar gene expression regulators demonstrated that fleQ controls the expression of numerous flagellar biosynthetic genes. Together with RpoN, FleQ controls transcription of 14 out of 31 flagellar class II genes, coding for the basal body, hook, and regulatory proteins. Unexpectedly, 7 out of 15 late flagellar genes class III and IV) are expressed dependent on FleQ but independent of RpoN. Thus, in contrast to the commonly accepted view that enhancer binding proteins as FleQ always interact with RpoN to initiate transcription, our results strongly indicate that FleQ of L. pneumophila regulates gene expression RpoN-dependent as well as RpoN-independent. Moreover, transcriptome analysis of a fleR mutant strain elucidated that FleR does not regulate the flagellar class III genes as previously suggested. Instead FleR regulates together with RpoN numerous protein biosynthesis and metabolic genes. Based on these experimental results our modified model for the transcriptional regulation of flagellar genes in L. pneumophila is that flagellar class II genes are controlled by FleQ and RpoN, while flagellar class III and IV genes are controlled in a fleQ-dependent but rpoN-independent manner. Although all L. pneumophila strains share the same complex life style, various pathotypes have evolved. This is reflected by the genomes, which contain e.g. genomic islands. The genomic island Trb-1 of L. pneumophila Corby, carries all genes necessary for a type-IV conjugation system, an integrase gene and a putative oriT site. The second aim of this thesis was to investigate the implication of this genomic island in conjugative DNA transfer. Using conjugation assays we showed that the oriT site located on Trb-1 is functional and contributes to conjugation between different L. pneumophila strains. As this is the first oriT site of L. pneumophila known to be functional our results provide evidence that conjugation is a major mechanism for the evolution of new pathotypes in L. pneumophila.
Legionella pneumophila, the causative agent of Legionnaires' disease is a facultative intracellular bacterium, which in the course of human infection multiplies in lung macrophages predominantly manifesting as pneumonia. The natural habitat of Legionella is found in sweet water reservoirs and man-made water systems. Virulent L. pneumophila spontaneously convert to an avirulent status at a high frequency. Genetic approaches have led to the identification of various L. pneumophila genes. The mip (macrophage infectivity potentiator) determinant remains at present the sole established virulence factor. The Mip protein exhibits activity of a peptidyl prolyl cis trans isomerase (PPiase), an enzyme which is able to bind the immunosuppressant FK506 and is involved in protein folding. The recently cloned major outer membrane protein (MOMP) could play a role in the uptake of legionellae by macrophages. Cellular models are useful in studying the intracellular replication of legionellae in eukaryotic cells. Human celllines and protozoan models are appropriate for this purpose. By using U 937 macrophage-like cells and Acanthamoeba castellanii as hosts, we could discriminate virulent and avirulent L. pneumophila variants since only the virulent strain was capable of intracellular growth at 37 oc. By using these systems we further demonstrated that a hemolytic factor cloned and characterized in our laboratory, legiolysin (lly), had no influence on the intracellular growth of L. pneumophila.
Legionella pneumophila generares exotoxins, cytolysins, proteases oc hemolysins that darnage host cells llke erythrocytes or rissue cu lrure cells. The gene for a new L. pneumophila hemolysin withour a proteolytic activiry was idemified, cloned in E. coli and sequenced. The gene producr was analysed by SDS-Polyacrylamide-gel-electrophoresis.
A hospital warm water system was monitored for the prcsence and distribution of lcgionellac. Subtyping of ten scletled Legionella pneumophiltl isolates. originating from four different sites in the system by using serogroup spccific antisera in an indircct immunofluorcscence tcst, rcvcalcd that nine of the tcn isolatcs belonged to scrogroup 6, while the remaining one was serogroup I 0. Two monoclonal antibodics (mAbs) spccific for a subgroup of serogroup 6 strains were further used for characterization. None of the strains reactcd with these mAbs. Genome analysis by elaborating Not I profiles using the pulscd field gel electrophoresis (PFGE) technique revealed that nearly all serogroup 6 isolates dcrived from different sites, including a new building connected hy a ring pipe. wcrc identical according to restriction fragment pattems. The patterns were distinguishable from those of the two L. pnewnophi/a serogroup 6 rcfcrencc strains, and ftom that of thc L. pneumophila scrogroup 10 isolate. These data arguc for a relatively homogeneaus L. pneunwpltila serogroup 6 population in the entire watcr system.
In this thesis, computational structure-based design approaches were employed to target the HIV-1 integrase and the macrophage infectivity potentiator (MIP) of Legionella pneumophila. The thesis yields valuable information about the mechanism of action of a known class of integrase inhibitors and a novel approach towards enzyme inhibition, which still is mainly unaddressed in current integrase research. For the MIP enzyme, two small-molecule MIP inhibitors were discovered. The computational studies of HIV-1 integrase have provided valuable information for IN inhibitor design. Docking experiments supported the hypothesis that the well-known diketo acid inhibitors enter the IN active site not as free ligands, but rather as metal complexes. These results help to reveal the mechanism of action of this important class of IN inhibitors.To give an impulse for the development of a novel class of inhibitors, a new strategy towards IN inhibition was introduced: An alternative binding site, the dimerization interface of an IN catalytic core domain monomer, was explored for inhibitor design. The lack of structural data of the free monomer was overcome by extensive MD studies. Snapshots derived from the MD simulation were used as protein input structures in a docking study with the inhibitory peptide YFLLKL to reveal its potential binding mode. The docking procedure showed that the peptidic ligand binds to a dimerization interface conformation which shows a Y-shaped binding site.. The next step was to address this protein conformation with small, non-peptidic molecules. The first strategy towards finding small-molecule interface binders was to create a pharmacophore model with hydrophobic features and shape constraints, aiming to find molecules with a good complementarity to the Y-shaped dimerization interface. Virtual screening yielded a total of 10 compounds, which all displayed good shape complementarity and favorable hydrophobic interactions. Unfortunately, none of the compounds showed a reproducible inhibitory activity in biological assays. Some doubts remain about the validity of the assay results: The use of BSA was critical, since it is not unlikely that BSA “intercepted” the hydrophobic candidate compounds. The first strategy towards finding small-molecule dimerization inhibitors was reconsidered: In the second approach, the satisfaction of hydrogen bonding residues at the dimerization interface, was of major interest. Two pharmacophore models were employed, which retrieved several hundred hit molecules. However, docking of these molecules showed that still many hydrogen bonding groups of the protein remained unaddressed by the ligands. Eventually, after visual inspection, only eight molecules were selected as candidate compounds for further testing (results pending). This small “yield” underlines the difficulties in finding interface binders: The IN dimerization interface is a peculiar target with frequently alternating basic, acidic, and hydrophobic residues. It is not a well-ordered binding site with continuous hydrophobic areas and distinct hydrogen bond donors / acceptors. Other protein-protein interfaces show such well-ordered binding sites. Accordingly, the peculiarity of the IN dimerization interface, in addition to the delicate task of disrupting protein-protein interactions at all, makes the development of IN dimerization inhibitors very challenging. For MIP, the studies revealed two experimentally validated MIP inhibitors, which significantly reduce MIP enzymatic activity. To our knowledge, no small-molecule MIP inhibitor has been reported in the literature so far. A detailed analysis of the available structural data of MIP and a comparison to the human PPIase counterpart, FKBP12, pointed out a conformational diversity among the MIP structures and a crucial difference between the two PPIases, which could be traced to mainly one residue (Tyr109). The detailed comparison of FKBP12 and MIP complex structures made it possible to give an explanation, why a ketoacyl-substituted pipecoline derivative most probably does not bind to MIP, but a sulfone-substituted pipecoline derivative does bind to MIP. Knowledge of Legionella MIP inhibitors could be transferred also to other organisms (e.g. trypanosoms), where homologous MIP proteins are also pathological factors.